Pharmasimple Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Pharmasimple's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Specialty Retail Industry Growth14.5%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Jun 2021

Recent past performance updates

Recent updates

One Analyst Just Shaved Their Pharmasimple SA (EPA:ALPHS) Forecasts Dramatically

Jul 31
One Analyst Just Shaved Their Pharmasimple SA (EPA:ALPHS) Forecasts Dramatically

Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven Soon

Apr 12
Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven Soon

Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven Soon

Dec 27
Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven Soon

Revenue & Expenses Breakdown

How Pharmasimple makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTPA:ALPHS Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2132-510
31 Mar 2139-310
31 Dec 2046-200
30 Sep 2045-200
30 Jun 2044-100
31 Mar 2036-200
31 Dec 1928-300
30 Sep 1926-300
30 Jun 1923-200
31 Mar 1920-200
31 Dec 1817-200
30 Sep 1818-200
30 Jun 1818-200
31 Mar 1819-200
31 Dec 1719-100
30 Sep 1717-100
30 Jun 1715-100
31 Mar 1713-100
31 Dec 1611-100
31 Dec 157000
31 Dec 145000
31 Dec 134000

Quality Earnings: Insufficient data to determine if ALPHS has high quality earnings.

Growing Profit Margin: Insufficient data to determine if ALPHS's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ALPHS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare ALPHS's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if ALPHS's earnings growth over the past year exceeded the Specialty Retail industry average.


Return on Equity

High ROE: ALPHS has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/02/09 23:45
End of Day Share Price 2024/02/09 00:00
Earnings2021/06/30
Annual Earnings2020/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharmasimple SA is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Florent Thy-TineTPICAP Midcap